text, label
Barclays assigns only a 20% chance that studies on a Gilead antiviral drug being done in China will succeed against Covid-19, 0
Central bank 'collateral damage' is skewing financial markets. As the economic cycle chugs on so does the chorus of concerns about the surging pile of corporate debt. But one longtime bond-market watcher thinks some of the loudest critics — central banks — may be hypocritical to criticize the “mispricing” of risk in corporate bonds without acknowledging their own role in creating the situation., 0
Congratulations to Phreesia (NYSE: $PHR) who was just named 2020 Best in KLAS for Patient Intake Management by the research and insights firm KLAS, 1
Hastings Technology Metals : Bulk Ore Sorting Trial Shows Outstanding Results, 1
Alibaba share sale for $13.B Hong Kong listing oversubscribed, 2
Alphabet and Facebook price targets cut at Barclays on weaker ad outlook. But the analysts affirmed both at overweight. They expect revenue declines but not as big as others do., 0
Morgan Stanley raised its rating on Nvidia to overweight from equal weight as the firm sees the stock racing even higher in 2020 after a solid performance in a competitive year among semiconductor companies, 1
Fed Chairman Jerome Powell says central bank ‘watching carefully’ as firms brace for wave of missed mortgage payments, 2
Exxon Mobil jumps after maintaining dividend and on hopes for production cut deal (XOM), 1
WWE shares plunged erasing more than $1 billion in market value after CEO Vince McMahon ousted two of the company’s top executives, 0
